Adler-Moore J - Search Results

1

Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals.

Wasmann RE, Smit C, van Dongen EPH, Wiezer RMJ, Adler-Moore J, de Beer YM, Burger DM, Knibbe CAJ, Brüggemann RJM. Wasmann RE, et al. Among authors: adler moore j. Clin Infect Dis. 2020 May 6;70(10):2213-2215. doi: 10.1093/cid/ciz885. Clin Infect Dis. 2020. PMID: 31588493 Free PMC article. Clinical Trial.

2

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.

Groll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM. Groll AH, et al. Among authors: adler moore j. Clin Infect Dis. 2019 May 2;68(Suppl 4):S260-S274. doi: 10.1093/cid/ciz076. Clin Infect Dis. 2019. PMID: 31222253 Free PMC article. Review.

3

Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.

Adler-Moore J, Lewis RE, Brüggemann RJM, Rijnders BJA, Groll AH, Walsh TJ. Adler-Moore J, et al. Clin Infect Dis. 2019 May 2;68(Suppl 4):S244-S259. doi: 10.1093/cid/ciz064. Clin Infect Dis. 2019. PMID: 31222254 Free PMC article. Review.

4

Pharmacology of Liposomal Amphotericin B: An Introduction to Preclinical and Clinical Advances for Treatment of Life-threatening Invasive Fungal Infections.

Walsh TJ, Lewis RE, Adler-Moore J. Walsh TJ, et al. Among authors: adler moore j. Clin Infect Dis. 2019 May 2;68(Suppl 4):S241-S243. doi: 10.1093/cid/ciz091. Clin Infect Dis. 2019. PMID: 31222252 Free PMC article. No abstract available.

5

Amphotericin B lipid preparations: what are the differences?

Adler-Moore JP, Proffitt RT. Adler-Moore JP, et al. Clin Microbiol Infect. 2008 May;14 Suppl 4:25-36. doi: 10.1111/j.1469-0691.2008.01979.x. Clin Microbiol Infect. 2008. PMID: 18430127 Free article. Review.

6

Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.

Smith PJ, Olson JA, Constable D, Schwartz J, Proffitt RT, Adler-Moore JP. Smith PJ, et al. J Antimicrob Chemother. 2007 May;59(5):941-51. doi: 10.1093/jac/dkm077. Epub 2007 Mar 30. J Antimicrob Chemother. 2007. PMID: 17400589

7

Liposomal amphotericin B for the treatment of visceral leishmaniasis.

Bern C, Adler-Moore J, Berenguer J, Boelaert M, den Boer M, Davidson RN, Figueras C, Gradoni L, Kafetzis DA, Ritmeijer K, Rosenthal E, Royce C, Russo R, Sundar S, Alvar J. Bern C, et al. Clin Infect Dis. 2006 Oct 1;43(7):917-24. doi: 10.1086/507530. Epub 2006 Aug 28. Clin Infect Dis. 2006. PMID: 16941377

8

Comparison between liposomal formulations of amphotericin B.

Adler-Moore JP, Gangneux JP, Pappas PG. Adler-Moore JP, et al. Med Mycol. 2016 Mar;54(3):223-31. doi: 10.1093/mmy/myv111. Epub 2016 Jan 14. Med Mycol. 2016. PMID: 26768369 Review.

9

Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products.

Olson JA, Adler-Moore JP, Jensen GM, Schwartz J, Dignani MC, Proffitt RT. Olson JA, et al. Antimicrob Agents Chemother. 2008 Jan;52(1):259-68. doi: 10.1128/AAC.00870-07. Epub 2007 Oct 29. Antimicrob Agents Chemother. 2008. PMID: 17967910 Free PMC article.

10

Liposomal amphotericin B and echinocandins as monotherapy or sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections.

Olson JA, George A, Constable D, Smith P, Proffitt RT, Adler-Moore JP. Olson JA, et al. Antimicrob Agents Chemother. 2010 Sep;54(9):3884-94. doi: 10.1128/AAC.01554-09. Epub 2010 Jul 6. Antimicrob Agents Chemother. 2010. PMID: 20606065 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters